Pharmacokinetics of 2’,3’-Dideoxy-5-fluoro-3’-thiacytidine in Rats

This publication has 21 references indexed in Scilit:

• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
  Proceedings of the National Academy of Sciences, 1992
• The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro
  Antimicrobial Agents and Chemotherapy, 1992
• Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive Subjects
  The Journal of Infectious Diseases, 1992
• Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
  Science, 1991
• Antiretroviral Activity, Biochemistry, and Pharmacokinetics of 3'-Azido-2',3'-Dideoxy-5-Methylcytidine
  Annals of the New York Academy of Sciences, 1990
• Zidovudine
  Drugs, 1989
• HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
  Science, 1989
• The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
  New England Journal of Medicine, 1987
• The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
  New England Journal of Medicine, 1987
• ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
  The Lancet, 1986